Table 1.
Mechanism of action of curcumin in colorectal cancer therapy (45).
| Experimental model (cell lines & animals) | Mechanism of action |
|---|---|
| HCT116, HCT116p53-/-, and SW480 cell lines (cell lines) |
↓ cellular proliferation ↑induced apoptosis and cell-cycle arrest ↑miR-34a ↓miR-27a |
| HCT15 cells (cell lines) |
↓proliferation ↑apoptosis ↓p53 and Prp4B |
| HCT116, HT29, HCT15, HCC2998, Colo205, Km12, and SW620 cells (cell lines) |
↓migration, invasion, and colony formation in vitro cells ↓tumor growth and liver metastasis in mice model. ↓Sp-1, FAK ↑E-Cadherin |
| RKO and HCT116 cells (cell lines) |
↓tumour growth, invasion and in vivo metastasis ↓miR-21 |
| HCT116 cells (cell lines) |
↑S and G2/M phase arrest ↑DNA damage |
| HCT116 and Caco-2 cells (cell lines) |
↑G(2)/M stage arrest ↑mitotic spindle abnormalities and defects in chromosomal congression ↑DNA damage |
| RKO and SW480 cells (cell lines) |
↑ROS, apoptosis ↓cell growth ↓SP1,SP3 and SP4 |
| LoVo-xenograft (Animal model) |
↑sensitivity to oxaliplatin, apoptosis ↑Bax, caspase-3, and PARP |
| HCT116-xenograft (Animal model) |
↑radiosensitivity ↓NF-κB |
| Patient-derived colorectal liver metastases xenografts (Animal model) |
↓cancer stem cell phenotypes ↑anti-proliferative and pro-apoptotic effects by FOLFOX treatment ↓number of ALDHhigh/CD133-cells |
| Orthotopically implanted CRC tumors (HCT116)- (Animal model) | ↓growth and metastasis ↑sensitivity to capecitabine ↓NF-κB |
| DSS-induced tumor mice (Animal model) |
↓disease activity index, ↓neoplasic lesions ↓ß-catenin, COX2, iNOS |